Compare IDEXX Laboratories, Inc. (IDXX) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Realty Income Corp — how do they compare? IDEXX Laboratories, Inc. trades at $571.77 (market cap $46.22B), while Realty Income Corp trades at $62.55 (market cap $58.56B). The key difference: Realty Income Corp is the larger of the two by market cap, and Realty Income Corp pays a 5.25% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | O | |
|---|---|---|
Market Cap | $46.22B | $58.56B |
Sector | Health | Real Estate |
52-Week High | $766.68 | $67.56 |
52-Week Low | $526.44 | $55.93 |
Enterprise Value | $47.12B | $89.19B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Realty Income (O) trades at $62.43, up 0.87% with a bearish technical signal despite bullish oscillators. The REIT reported three consecutive quarterly EPS misses but maintains strong fundamentals with 92.56% gross margins and 21.23% net income margin. Recent news highlights a $875 million convertible notes offering and the company's 115th consecutive dividend increase, supporting its monthly dividend reputation. Revenue growth continues from $5.3B in 2024 to $5.7B in 2025, though debt-to-asset ratio has risen to 39.93%.
The stock presents a mixed outlook with analyst consensus at Buy (41%) and $67.29 price target offering 7.8% upside. Key opportunities include reliable dividends and portfolio expansion into data centers, while risks involve rising leverage and interest rate sensitivity. Technical resistance at $62-63 levels may cap near-term gains despite oversold RSI conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
